Amarin Corp. plc, of Dublin, disclosed the presentation of findings from two studies, a retrospective study in which patients were switched from an EPA plus DHA combination product to EPA-only Vascepa (icosapent ethyl) as well as a sub-analysis of the Anchor trial at scientific cardiovascular meetings. The eicosapentaenoic acid (EPA) plus docosahexaenoic acid (DHA)to EPA-only switch study investigated the effect of EPA-only omega-3 therapy compared to EPA plus DHA therapy on multiple patient lipid parameters. Results showed a reduction in both triglyceride and low-density lipoprotein cholesterol levels with EPA-only therapy in most of these high-risk statin-treated patients. The Anchor sub-analysis related to a study that examined the effect of EPA on high-risk statin-treated patients with persistently high triglyceride levels, showing that icosapent ethyl increased EPA in plasma and red blood cells in a linear, dose-dependent fashion consistent with its triglyceride-lowering effect, Amarin said.